Background Cardiovascular-kidney-metabolic (CKM) multimorbidity is increasingly recognized as a major global health concern. Although osteoarthritis (OA) is traditionally viewed as a degenerative joint condition, recent evidence suggests it may reflect systemic inflammation and metabolic dysfunction. However, its role as a potential clinical marker of CKM multimorbidity remains unclear. Methods This population-based cohort study included 1,842 participants with osteoarthritis from a community registry in China. CKM multimorbidity was defined as the sequential development of cardiovascular disease (CVD), chronic kidney disease (CKD), and type 2 diabetes mellitus (T2DM). Participants were followed for incident CKM events. Logistic regression models estimated odds ratios (ORs) for new-onset, double, and triple CKM outcomes. A multi-state model was applied to assess progression trajectories between disease stages. Results Over the study period, 32.6% of participants developed at least one CKM condition, 27.1% progressed to double CKM, and 5.4% developed triple CKM. Higher osteoarthritis burden was associated with increased risk of CKM multimorbidity. Adjusted ORs (95% CI) for new-onset, double, and triple CKM were 2.64 (2.33 – 3.00), 2.40 (2.11 – 2.72), and 1.49 (1.21 – 1.84), respectively. Multi-state modeling confirmed that osteoarthritis. Conclusion Osteoarthritis is strongly associated with the onset and progression of CKM multimorbidity. As a clinically observable and common condition, OA may serve as an early indicator for identifying individuals at heightened risk of multi-organ metabolic decline. These findings support the integration of OA status into risk stratification frameworks for CKM disease prevention and management.
Zou et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: